Primary Care Update Kauai

New Drugs Part 1

• Identify 10 – 20 new medications .

• Discuss the use, side effects, drug-drug interactions, and benefits of each of the medications.

• Discuss updates related to labeling, indications, risks associated with various medications

Obesity Case Studies:

·      Discuss the health risks associated with obesity .

·      Identify the various behavioral modalities utilized to assist with weight loss .

·      Discuss pharmacologic strategies for weight stabilization or loss in the overweight or obese individual

COPD

·      Identify statistics regarding COPD.

·      Discuss the signs and symptoms of COPD.

·      Discuss treatment options for COPD .

Fibromyalgia

·      Identify new diagnostic criteria for fibromyalgia .

·      Discuss the various non-pharmacologic and pharmacologic treatments available for individuals with fibromyalgia .

·      Review multimodal treatments based upon the evidence .

New Drugs Part 2

·      Identify 10 – 20 new medications

·      Discuss the use, side effects, drug-drug interactions, and benefits of each of the medications.

·      Discuss updates related to labeling, indications, risks associated with various medications.

Pediatric Pharmacotherapeutics: 

·      Identify ways in which children are different than adults in terms of pharmacotherapeutics

·      Discuss common pediatric prescribing errors.

·      Discuss strategies to prevent pediatric prescribing errors.

·      Identify medications with new pediatric approvals.

COVID–Drug Interactions

·      Improve ability to identify disparity gaps in treatment, management, and drug interactions in outpatients with COVID-19.

·      Gain greater confidence in their ability to assess and manage outpatients with COVID-19 for drug interactions.

·      Enhance their understanding of the national COVID-19 Treatment Guidelines for outpatients with COVID-19.

CKD Treatment in Primary Care

·      Detect and recognize CKD in patients with reduced kidney function, including in early stages of disease.

·      Implement screening for albuminuria in patients with diabetes in clinical practice to identify CKD as early as possible.

·      Initiate therapy with evidence-based therapies, including newer agents, for patients with CKD when indicated.

Antibiotic Update: Respiratory Infections:

·      Identify statistics related to incidence/prevalence of various respiratory conditions.

·      Discuss the signs and symptoms of pneumonia, ABRS, AOM, AECB.

·      Discuss treatment pharmacologic options for the above conditions.

New Therapies for Resistant Hypertension:

·      Discuss the definition of resistant hypertension .

·      Identify the work up for the patient with resistant hypertension.

·      Discuss the treatment options for patient with resistant hypertension .

OA and RA Guidelines 2023

·      Discuss the pathophysiology of osteoarthritis and rheumatoid arthritis.

·      Identify the non-pharmacologic and pharmacologic agents available for the treatment of osteoarthritis and RA.

·      Compare and contrast newer pharmacologic agents with older agents with regard to benefits, risks, side effects, and drug interactions.

Immunizations:

·      Identify the 2024 recommended vaccinations and schedule for individuals across the lifespan.

·      Discuss the benefits and side effects of the various vaccines for individuals across the lifespan.

·      Discuss strategies to improve vaccine hesitancy